MAIA Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
MAIA Biotechnology, Inc. (MAIA) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 3.64 million shares for the 6-month period ending 2025-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2026-08-10
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-06-30 was 1.06M shares.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-03-31 was 2.58M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month |
|---|---|---|
| 2025-06-30 | 1.06M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 3.64M shares 10-Q · filed 2026-08-10 |
| 2025-03-31 | 2.58M shares 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |